anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Due to the short duration of inpatient stays and increasing outpatient treatment it is assumed that the incidence of delirium in ophthalmology is underestimated. The overall aim of this study was to record the incidence of delirium in ophthalmology through long-term follow-up.
METHOD: The study was divided into 2 groups. In group A delirium events were recorded retrospectively based on the discharge reports of all inpatients at the University Clinic Freiburg, Clinic for Ophthalmology from 1 January 2020 to 31 December 2022. In group B delirium events were recorded prospectively by the Augennetz Südbaden (Eye Network South Baden, ANSB) in the period 60-120 days after ophthalmological surgery.
RESULTS: During the study period of the retrospective analysis a total of 16,384 patients were treated as inpatients. There was evidence of a total of 7 new delirium events. This corresponds to a proportion of 0.04%. A total of 12,381 patients were assessed by the ANSB, including 11,530 outpatient cataract operations. There were indications of 31 delirium events, which corresponds to a proportion of 0.25%.
CONCLUSION: The long-term prospectively recorded delirium events suggest that the incidence of delirium in the inpatient setting is underdiagnosed; however, postoperative delirium appears to be rare in ophthalmology in relation to the high number of procedures.
A percutaneously absorbable preparation which contains norethisterone, estradiol or ester thereof, each of which is highly absorbable percutaneously, can readily be stuck to the skin, and is lowly skin irritating. It is prepared by applying a pressure-sentitive adhesive layer comprising a drug and a pressure-sensitive adhesive to one side of a support. The drug comprises at least one member selected from among norethisterone, estradiol and pharmacologically acceptable esters thereof, while the adhesive comprises a copolymer composed of 20-55 mol. % of vinylpyrrolidone and 80-45 mol. % of alkyl (C 4  -C 18 ) (meth)acrylate. The adhesive layer further contains a sorbifacient comprising 0.1-10 wt. % of at least one member selected from among dicarboxylic acids, hydroxy carboxylic acids, plyoxyethylene alkyl ethers and amide compounds and 5-40 wt. %, both based on the adhesive layer, of a higher fatty acid ester prepared from a C 10  -C 18  fatty acid and a C 1  -C 20  alcohol and also contains a cohesive force improver.
BACKGROUND: Adenoviral vector-based COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) is rare but carries significant risks of mortality and long-term morbidity. The underlying pathophysiology of severe disease is still not fully understood. The objectives were to explore the pathophysiological profile and examine for clinically informative biomarkers in patients with severe VITT.
METHODS: Twenty-two hospitalized patients with VITT, 9 pre- and 21 post-ChAdOx1 vaccine controls, were recruited across England, United Kingdom. Admission blood samples were analyzed for cytokine profiles, cell death markers (lactate dehydrogenase and circulating histones), neutrophil extracellular traps, and coagulation parameters. Tissue specimens from deceased patients were analyzed.
RESULTS: There were strong immune responses characterized by significant elevations in proinflammatory cytokines and T helper 1 and 2 cell activation in patients with VITT. Markers of systemic endothelial activation and coagulation activation in both circulation and organ sections were also significantly elevated. About 70% (n = 15/22) of patients met the International Society for Thrombosis and Haemostasis criteria for disseminated intravascular coagulation despite negligible changes in the prothrombin time. The increased neutrophil extracellular trap formation, in conjunction with marked lymphopenia, elevated lactate dehydrogenase, and circulating histone levels, indicates systemic immune cell injury or death. Both lymphopenia and circulating histone levels independently predicted 28-day mortality in patients with VITT.
CONCLUSION: The coupling of systemic cell damage and death with strong immune-inflammatory and coagulant responses are pathophysiologically dominant and clinically relevant in severe VITT.
A total of 32 sessions (2 sets of 16 sessions) of TPS will be delivered, each lasting 30 minutes. Each set includes 3 sessions per week in the first 2 weeks and then 1 session per week in the subsequent 10 weeks.
Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Monotherapy

The recommended dose of fulvestrant injection is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter [see Clinical Studies (14)].

Combination Therapy 

When fulvestrant injection is used in combination with palbociclib, abemaciclib, or ribociclib, the recommended dose of fulvestrant injection is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 to 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days1, 15, 29,and once monthly thereafter.

When fulvestrant injection is used in combination with palbociclib, the recommended dose of palbociclib is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food. Refer to the Full Prescribing Information for palbociclib.

When fulvestrant injection is used in combination with abemaciclib, the recommended dose of abemaciclib is 150 mg orally, twice daily. Abemaciclib may be taken with or without food. Refer to the Full Prescribing Information for abemaciclib.

When fulvestrant injection is used in combination with ribociclib, the recommended dose of ribociclib is 600 mg taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. Ribociclib can be taken with or without food. Refer to the Full Prescribing Information for ribociclib.

Pre/perimenopausal women treated with the combination of fulvestrant injection plus palbociclib, abemaciclib, or ribociclib, should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards [see Clinical Studies (Error! Hyperlink reference not valid.)].
OBJECTIVE: Despite treatment advances, pain remains a serious problem for many children with juvenile idiopathic arthritis (JIA). To better understand pain in children with JIA and identify potentially modifiable factors, this study evaluated Patient-Reported Outcomes Measurement Information System (PROMIS) Pediatric Pain Interference (PI) and its relationships with other pain measures and demographic, clinical, psychosocial, and functional variables.
METHODS: This cross-sectional, observational, multicenter study used descriptive statistics and a mix of bivariate and multivariable analyses to describe PI and characterize relationships with other measures and variables.
RESULTS: Among 355 children with JIA, 27% reported moderate or severe PI and 13.3% reported daily pain. PI correlated with other pain measures. Increasing age, decreasing disease duration, and increasing number of active joints, as well as presence of active disease, steroid treatment, and biologic treatment, were associated with greater PI. All PROMIS psychosocial and functional measures were associated with PI in the expected direction except for PROMIS Pediatric Physical Activity, which showed no association. In multivariable analyses, only PROMIS Fatigue, PROMIS Mobility, and the exploratory interaction of PROMIS Anxiety and disease-modifying antirheumatic drug treatment were significant.
CONCLUSION: Moderate and severe PI was prevalent in this sample of children with JIA. PI increased with age and indicators of disease activity, but was more strongly associated with increasing fatigue and decreasing mobility. Findings support the use of PI as a short, easily administered multidimensional pain measure as part of routine clinical care. Fatigue, mobility, and disease activity should be assessed further when PI is high.
The investigators aim for six sessions of anodal stimulation over the right primary motor area contralateral to the orofacial pain (C3 or C4 in 10-20 EEG system) with cathode above the frontal area ipsilateral to the orofacial pain (Fp1 or Fp2) using HDCstim by Newronika S.r.l., Italy. The therapy will be administered over two weeks (Mon, Wed, Fri) to ensure a washout period of 48 to 72 hours between applications. The current of 2 mA will be delivered via silicone electrodes inserted into saline (0.9%) filled cellulose sponges, anode 5x5cm, cathode 6x8cm, for 20 minutes with 20 seconds of both ramp-up and ramp-down. An International 10-20 EEG system will be used to determine the stimulation location, and dedicated EEG caps will be used to ensure consistency between applications.
NEW MATERIAL:The compound of formula I (Z is group of formula II or formula III; A is group of formula IV, formula V, etc.) and its salt. EXAMPLE:cis-2-[( 3,5-Bistrifluoromethylphenyl )-aminocarbonyl]-cyclohexane-carboxylic acid. USE:It has antispasmodic action, antianoxic action, antianxiety action and sedative action, and is useful as a remedy and preventive for various diseases causing spasm, e.g. epilepsy, sequela of cerebrovascular disturbance, sequela of cephatic lesion, etc. PROCESS:The carboxylic acid amide compound of formula I wherein Z is group of formula II can be prepared by reacting 3,5-bistrifluoromethyl-aniline with the carboxylic acid anhydride of formula VI. The obtained amide compound can be converted to a carboxyimide compound of formula I wherein Z is group of formula III by dehydration.
This arm will start with a one-time 100mg dose and progress to twice daily dosing for 3 days, every 12 hours. Study cohort will be same 9 subjects with asthma. DHEA dose will be 100mg via slow release capsules. Endpoints will be serum DHEA and DHEA-S levels at 10, 20, 30, 60 min \& 2, 4, 6, 8, 12h after administration.
Nonunion is an extremely rare complication in distal radius fractures and is most likely to occur in patients with conditions such as diabetes, peripheral vascular disease, or alcoholism. Diagnosis of nonunion is based on the absence of radiographic signs of union at 6 months. Treatment should be individualized but options are reconstructive procedures or wrist arthrodesis. In volar plating and often by the fracture injury itself, the complete pronator quadratus is stripped off the volar radius. Thus, the intraosseous collateral circulation must be sufficient for clinical healing. Any operative approach to the distal radius fracture should not compromise both volar radial and the dorsoulnar arteries.

While the branches to the pronator quadratus must be sacrificed in a palmar approach, the distal perforator can and should be spared. This is true even in the flexor carpi radialis extended approach. In distal radius fractures, when the normal outward flow of blood through the cortex is blocked, the periosteal arterioles have more ability than medullary arterioles to function and proliferate.
Rituximab 375 mg/m\^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m\^2 IV, Doxorubicin 50 mg/m\^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m\^2 IV followed by 800 mg/m\^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m\^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m\^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.
Pregnancy is thought to be associated with the remediation of some disease and exacerbation of other conditions. Anecdotal case reports suggest that uveitis may remit or improve during pregnancy and recur in the postpartum period. This observation is supported by findings in an experimental autoimmune uveitis model in mice. We propose to study the natural history of ocular inflammation in a series of pregnant women who have had ocular inflammation (uveitis) in the two year period prior to becoming pregnant. Women will be enrolled between 2 and 20 completed weeks of gestation at which time they will receive a complete ophthalmologic examination and will have blood drawn for cytokine and hormone evaluation. These procedures will be repeated at monthly intervals until 6 months postpartum. Treatment of uveitis will ensue as medically indicated and in consultation with the woman's obstetric care provider. The goal of this investigation is to determine whether cytokine levels are correlated with disease expression. Such information may be useful to inform decisions about how to best manage pregnant and postpartum uveitis patients in the future.
OBJECTIVE: To study the risk of lupus nephritis flare (LNF) or severe lupus flare (SLF) as a function of B cell count kinetics in lupus nephritis (LN) patients after they achieve at least a partial renal response (PRR) with induction treatment that includes rituximab (RTX) and/or belimumab (BLM).
METHODS: We performed a retrospective analysis of a cohort of 19 patients with severe LN that received a B cell agent (BCA), RTX and/or BLM, as part of an initial treatment regimen for an LN flare and had subsequent CD19+ B cell measurements in peripheral blood. We then characterized the follow-up periods, after B cell depressions occurred and PRR were achieved, by the corresponding trajectories of B cell counts (BCC). Time periods with sustained low BCC were type 1 (T1) episodes, while those with repletion of BCC>100 cells/μL were called type 2 (T2) episodes. Time periods with rapid BCC repletion, defined as >50 cells/μL in ≤6 months, were called T2b episodes. Corresponding C3, C4, and anti-dsDNA levels were recorded for each episode. The time from PRR until an event, either a LNF or SLF, or to censoring, either at the end of the study period or the end of available patient follow-up, was assessed for each episode type. Kaplan-Meier survival analysis was used to compare time to flare between T1 and T2 episodes.
RESULTS: There were 26 episodes of B cell depression. Seventeen (65%) were T1 and 9 (35%) were T2. Compared to T1 episodes, T2 episodes were 9.0 times more likely to result in flare over the follow-up period (hazard ratio (HR) = 9.0, 95% CI for HR = 2.2-36.7); this risk was even larger for T2b vs T1 episodes. Median BCC was 14 cells/μL in T1 and 160 cells/μL in T2 episodes. Both C3 and C4 levels significantly increased over the duration of the episode in T1 episodes only.
CONCLUSION: Sustained low BCC was associated with prolonged serologic and clinical response, whereas repletion, and particularly rapid repletion, of B cells after treatment with BCA was associated with subsequent disease flare.
PROBLEM TO BE SOLVED: To obtain the pectin useful in the fields of food, medicaments, compound articles, etc., by dissolving or dispersing pectin into water, then adding an org. acid thereto and subjecting this pectin to heating or a heat treatment under a high pressure. SOLUTION: The pectin [a preferable raw material is a high methoxyl pectin and is not mixed with glucose and sucrose; for example, 'BROWN NF (R)'] is dissolved or dispersed in the water. The compounding ratio of the raw material and the water is preferably <=30(wt.)%. Next, the org. acid, more preferably citric acid, is added at 10 to 100% to the pectin and the pectin is heated for 20 minutes to 4 hours preferably at 60 to 130 deg.C or is subjected to the heat treatment under the high pressure for 60 seconds to 1 hour in a range of 1 to 3,000atm, by which the desired pectin is obtd.
Disclosed herein are siHybrids used for gene silencing. An siHybrid is a short double-stranded molecule comprises of one strand of DNA and one strand of RNA, annealed together, with a 2-base overhang at each 3' end. In addition to DNA  and RNA, it may contain PNA or other nucleic acid analogs. siHybrids can silence a gene with greater magnitude and duration than siRNA and they can also silence bacterial genes, which siRNA cannot. siHybrids are ideal candidates for pharmaceutical and therapeutic agents for treating diseases caused by an over-expressed gene or a cancerous gene. They also can be used as antibiotics when targeted to a vital and unique bacterial gene. siHybrids can be used as antivirus agents, fungicides, herbicides or pesticides. An appropriate siHybrid can be designed to silence any gene in any cell of any organism.
To help maximize the impact of scientific journal articles, authors must ensure that article figures are accessible to people with color-vision deficiencies (CVDs), which affect up to 8% of males and 0.5% of females. We evaluated images published in biology- and medicine-oriented research articles between 2012 and 2022. Most included at least one color contrast that could be problematic for people with deuteranopia ('deuteranopes'), the most common form of CVD. However, spatial distances and within-image labels frequently mitigated potential problems. Initially, we reviewed 4964 images from eLife, comparing each against a simulated version that approximated how it might appear to deuteranopes. We identified 636 (12.8%) images that we determined would be difficult for deuteranopes to interpret. Our findings suggest that the frequency of this problem has decreased over time and that articles from cell-oriented disciplines were most often problematic. We used machine learning to automate the identification of problematic images. For a hold-out test set from eLife (n=879), a convolutional neural network classified the images with an area under the precision-recall curve of 0.75. The same network classified images from PubMed Central (n=1191) with an area under the precision-recall curve of 0.39. We created a Web application (https://bioapps.byu.edu/colorblind_image_tester); users can upload images, view simulated versions, and obtain predictions. Our findings shed new light on the frequency and nature of scientific images that may be problematic for deuteranopes and motivate additional efforts to increase accessibility.
It will apply a usual training program for 4 weeks, 4hours and 30 min per week distributed equally over 3 days in the week. In each session, it was performed 8 submaximes-dynamic apnoeas with 3-minute recovery between each one. Then was performed a maximal-dynamic apnoea. To finish the session, was performed a continuous training of free style swimming at moderate effort over 30 minutes.
Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
In group I, ISCB will be performed with patients in the supin position. US probe will be placed in transverse plane at the level of cricoid cartilage. The prob will be moved laterally when the artery is visualized. The needle will be inserted in a medial-to-lateral direction after the brachial plexus between the scalen muscles is visualized. Then, 5 ml normal saline will be enjected for correction of the needle with in-plane technique. Following confirmation of the correct position of the needle 30 ml %0.25 bupivacaine will be administered for block.
System for remote monitoring of the effects of a medicament (4) administered in a patient (1). <??>System for remote monitoring of the effects of a medicament (4) administered to a patient (1) comprises a database (11a), which carries a data file relating to the patient and the medication together with the expected performance. The actual performance data are taken at a receiver (11b) to be recorded for comparison with the expected performance. The computer (11) has a software program to implement the storage of the nominal data and, also, draw comparisons with the actual data. The patient carries a monitor (15) to register appropriate parameters, for subsequent transmission to the computer center (10).
PROBLEM TO BE SOLVED: To obtain a dermal preparation for external use having suppressing actions on melanogenesis, inhibiting actions on the tyrosinase activities and further on proteases and suppressing actions on elastases. SOLUTION: This dermal preparation for external use is obtained by blending an extract of Meniran (botanical name: Phyllanthuss niruri L.) which is a plant belonging to the genus Phyllanthuss of the family Euphorbiaceae or Kemiri (botanical name: Aleuritis moluccana) belonging to the genus Aleuritis as an active ingredient in an amount of 0.0005-20wt.%, preferably 0.001-10wt.% expressed in terms of a dried substance therein. The plants are those growing in especially a dry grassland, a pasture, etc., of Indonesia and the extract is obtained by immersing the whole herb of the plants, etc., together with an extracting solvent (e.g. ethanol) therein or refluxing the mixture under heating, then filtering the mixture and concentrating the resultant filtrate.  The dermal preparation for the external use is capable of manifesting effects on lightening of the color and beautifying and whitening of pigmentation, dermal stains, ephelides, chloasma, etc., after sunburn and has effects on reduction in various dermatoses, skin roughening, dry skin, etc., and further restoration and maintenance of tenseness and elasticity of the skin, prevention of the skin from aging and maintenance of the fresh skin. The active ingredient can be prepared as an ointment, a cream, a milky lotion, a lotion, a pack, a bathing agent, etc.
Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this "body" scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma).